Schering Hepatitis Innovations
About Hepatitis
Treatment for Hepatitis
For Health Care Professionals
bullet bullet General Information
bullet bullet Overview of Hepatitis
Product Inserts
Navigation Bottom
Overview of Hepatitis

An Emerging Public Health Threat
Hepatitis C, B, and A
Hepatitis C
Diagnosing Chronic Hepatitis C
Major Risk Factors for Hepatitis C and B

An Emerging Public Health Threat

Hepatitis C currently infects about 4 million Americans. Most are unaware of their infection. Hepatitis C infects an additional 30,000 people each year, according to estimates by the National Institutes of Health (NIH). Called "an emerging public health threat," hepatitis C is a leading cause of cirrhosis and liver cancer. Hepatitis C is also now the leading reason for liver transplantation in the United States.

Return to Top

Hepatitis C, B, and A

Of six known hepatitis viruses — C, A, B, D, E, and G — the most common are hepatitis C, B, and A. Hepatitis A (HAV), the least serious form, does not progress to chronic disease. A small proportion of individuals with hepatitis B — 5 to 10% — develops chronic disease.

Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated. Hepatitis C will cause approximately 10,000 deaths annually, and hepatitis B will cause 5,000 deaths, according to estimates by the American Liver Foundation. And unlike other life-threatening illnesses, hepatitis usually claims individuals in their most productive years; almost 50% of deaths occur before the age of 60.

Hepatitis C progresses to a chronic disease in about 85% of individuals who contract acute hepatitis C. About 20% of those patients will develop cirrhosis after 20 years with hepatitis C. The risk of developing liver cancer (hepatocellular carcinoma, HCC) following cirrhosis is 1 to 4% each year, not overall risk. This means that, if 100,000 patients are cirrhotic, 1000-4000 will develop HCC each year, a total of 10,000 to 40,000 at the end of 10 years.

Although hepatitis C, B, and A remain diseases that warrant better preventive measures, some progress has been made. Vaccines exist for hepatitis A & B. Hepatitis C has no vaccine, but progress has been made in the areas of better diagnostic techniques and more effective treatments for the disease.

Return to Top

Hepatitis C

Hepatitis C is a slow, progressive virus that can cause liver injury over years, even decades, often without specific symptoms. Symptoms of hepatitis C may include loss of appetite, fatigue, decreased exercise tolerance, arthralgia, vomiting, stomach pain, depression and — in rare cases — jaundice. Chronic fatigue is the most salient symptom.

Hepatitis C has an average incubation period of 6 to 7 weeks, with a range extending from 2 weeks to 26 weeks. Symptomatic illness develops in about 30 to 40% of individuals with acute infection; 20 to 30% will have jaundice.

Return to Top

Major Risk Factors for Hepatitis C and B

Hepatitis C
  • Hemophilia patients who received clotting agents prior to 1987
  • Hemodialysis
  • Organ transplant prior to 1992
  • IV drug use
  • Blood transfusion prior to 1992
  • Needle-stick injury
  • Tattooing with contaminated needles
  • Body piercing
  • Sexual activity with multiple partners
Hepatitis B
  • Hemodialysis
  • Patients of custodial institutions for developmentally disabled
  • Exposure to blood/blood clot products
  • Needle-stick injury
  • Sexual activity with multiple (heterosexual or homosexual) partners
  • IV drug use
  • Infants of HBV-positive mothers
  • Tattooing with contaminated needles
  • Body piercing


Return to Top

Terms and ConditionsPrivacy Policy
Copyright © 2002, Schering Corporation, Kenilworth, NJ 07033. All rights reserved.
Schering Hepatitis Innovations Home Search Site Map Glossary Take Our Survey